Poor prognosis acute myelogenous leukemia: 1 – response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine)
| Autor: | Jerome Loew, Ahmad Jajeh, Angel G. Galvez, Stephanie A. Gregory, Tanja Andric, Steve Creech, Sefer Gezer, Wei-Tong Hsu, Parameswaran Venugopal, David Slivnick, Solomon S. Adler, Richard A. Larson, Harvey D. Preisler |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Population Pilot Projects Radiation-Protective Agents Blastic Phase Gastroenterology Myelogenous Amifostine hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans education Aged Aged 80 and over Acute leukemia Mitoxantrone education.field_of_study business.industry Cytarabine Hematology Middle Aged Prognosis medicine.disease Surgery Leukemia Myeloid Acute Leukemia Treatment Outcome Oncology business medicine.drug |
| Zdroj: | Leukemia Research. 24:671-680 |
| ISSN: | 0145-2126 |
| Popis: | Twenty patients with poor prognosis AML and four patients in the blastic phase of a myeloproliferative disorder were treated with two 'pulses' of therapy each consisting of two doses of high dose araC (separated by 12 h) followed by a single dose of mitoxantrone. The pulses were separated by 96 h. Amifostine was then administered tiw. The median age of the population was 68 years with 88% of patients having had either a prior MDS, MPD or toxic exposure. The acute leukemia of 58% of patients either entered a CR or reverted to preleukemic state. For patients under 70 years of age, treatment produced 62% CRs with a leukemia free decision marrow in 77%. For patients over 70 years the CR rate was 27% with 36% of patients having a leukemia free decision marrow. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect